Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Vaccine ; 41(2): 486-495, 2023 01 09.
Artículo en Inglés | MEDLINE | ID: mdl-36481106

RESUMEN

INTRODUCTION: Supplementary immunization activities (SIAs) aim to interrupt measles transmission by reaching susceptible children, including children who have not received the recommended two routine doses of MCV before the SIA. However, both strategies may miss the same children if vaccine doses are highly correlated. How well SIAs reach children missed by routine immunization is a key metric in assessing the added value of SIAs. METHODS: Children aged 9 months to younger than 5 years were enrolled in cross-sectional household serosurveys conducted in five districts in India following the 2017-2019 measles-rubella (MR) SIA. History of measles containing vaccine (MCV) through routine services or SIA was obtained from documents and verbal recall. Receipt of a first or second MCV dose during the SIA was categorized as "added value" of the SIA in reaching un- and under-vaccinated children. RESULTS: A total of 1,675 children were enrolled in these post-SIA surveys. The percentage of children receiving a 1st or 2nd dose through the SIA ranged from 12.8% in Thiruvananthapuram District to 48.6% in Dibrugarh District. Although the number of zero-dose children prior to the SIA was small in most sites, the proportion reached by the SIA ranged from 45.8% in Thiruvananthapuram District to 94.9% in Dibrugarh District. Fewer than 7% of children remained measles zero-dose after the MR SIA (range: 1.1-6.4%) compared to up to 28% before the SIA (range: 7.3-28.1%). DISCUSSION: We demonstrated the MR SIA provided considerable added value in terms of measles vaccination coverage, although there was variability across districts due to differences in routine and SIA coverage, and which children were reached by the SIA. Metrics evaluating the added value of an SIA can help to inform the design of vaccination strategies to better reach zero-dose or undervaccinated children.


Asunto(s)
Sarampión , Rubéola (Sarampión Alemán) , Humanos , Niño , Lactante , Estudios Transversales , Programas de Inmunización , Sarampión/prevención & control , Rubéola (Sarampión Alemán)/prevención & control , Vacunación , Vacuna Antisarampión , Inmunización
2.
Lett Appl Microbiol ; 65(5): 354-365, 2017 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-28741682

RESUMEN

Over the last three decades, successful implementation of the diphtheria vaccination in the developed and developing countries has reduced the infections caused by the toxigenic strains of Corynebacterium diphtheriae, but a concomitant increase in the invasive infections due to the nontoxigenic strains was seen. In addition, the recent reports on the emergence of nontoxigenic toxin gene-bearing strains, having the potential to revert back to toxigenic form poses a significant threat to human beings. Besides infections caused by C. diphtheriae, the emergence of the respiratory, cutaneous and invasive infections by related pathogenic Corynebacterium species like C. ulcerans and C. pseudotuberculosis, complicate the diagnosis and management of infection. These observations together with the widespread prevalence of diphtheria in the vaccine era, necessitates the strengthening of the epidemiological surveillance and laboratory diagnosis of the pathogen. This review provides the overview of the advantages and limitations of different molecular methods and the role of MALDI-TOF in the laboratory diagnosis of Diphtheria. The contribution of next generation sequencing technology and different genotyping techniques in understanding the pathogenicity, transmission dynamics and epidemiology of the C. diphtheriae is discussed.


Asunto(s)
Vacunas Bacterianas/aislamiento & purificación , Infecciones por Corynebacterium/diagnóstico , Corynebacterium/aislamiento & purificación , Vacunas Bacterianas/genética , Técnicas de Laboratorio Clínico , Corynebacterium/genética , Infecciones por Corynebacterium/microbiología , Genotipo , Secuenciación de Nucleótidos de Alto Rendimiento , Humanos
3.
Dermatol Online J ; 8(2): 2, 2002 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-12546757

RESUMEN

Propionibacterium acnes (P. acnes), an anaerobic pathogen, plays an important role in the pathogenesis of acne and seems to initiate the inflammatory process by producing neutrophil chemotactic factors (NCF). Once neutrophils attracted by bacterial chemoattractants reach the inflamed site, they release inflammatory mediators such as lysosomal enzymes and reactive oxygen species (ROS). Previously, it has been shown that antibiotics may affect acne by means other than their anti-bacterial effects. Thus, we investigated the effect of subminimal inhibitory concentration (sub-MIC) of tetracycline and erythromycin on production of NCF and ROS. NCF was tested in vivo in a mouse model and ROS was estimated on human PMNL in vitro, by nitroblue tetrazolium dye reduction test (NBT) and cytochrome-C reduction test. Tetracycline (CS-T) and Erythromycin (CS-E) treated cultures showed a significant reduction of 35.8% and 58.3% in NCF production respectively, as compared to P. acnes stimulated cultures. Tetracycline and erythromycin at their sub-MIC also significantly inhibited release of ROS from human PMNL. Thus, tetracycline and erythromycin, besides having antibacterial activity, also have an anti-inflammatory action. These antibiotics reduce the capacity of P. acnes to produce NCF, as well decrease its ability to induce ROS from PMNL.


Asunto(s)
Antiinflamatorios/farmacología , Factores Quimiotácticos/biosíntesis , Quimioterapia Combinada/farmacología , Eritromicina/farmacología , Neutrófilos/efectos de los fármacos , Neutrófilos/inmunología , Propionibacterium acnes/inmunología , Especies Reactivas de Oxígeno/metabolismo , Tetraciclina/farmacología , Acné Vulgar/tratamiento farmacológico , Antiinflamatorios/uso terapéutico , Factores Quimiotácticos/antagonistas & inhibidores , Grupo Citocromo c/metabolismo , Relación Dosis-Respuesta a Droga , Quimioterapia Combinada/uso terapéutico , Eritromicina/uso terapéutico , Humanos , Inflamación/tratamiento farmacológico , Inflamación/inmunología , Neutrófilos/enzimología , Neutrófilos/microbiología , Oxidación-Reducción/efectos de los fármacos , Propionibacterium acnes/efectos de los fármacos , Propionibacterium acnes/patogenicidad , Especies Reactivas de Oxígeno/antagonistas & inhibidores , Superóxidos/antagonistas & inhibidores , Superóxidos/metabolismo , Tetraciclina/uso terapéutico , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...